Company intelligence / Profile preview

Hadasit

Ownership: Public · HDST-M
Development stage: Other

Overview

Hadasit commercializes medical innovations originating from Hadassah University Medical Center. It has spun off over 50 companies, holds more than 250 active patent families, and its portfolio includes therapeutics, diagnostics, devices, digital health solutions. Notable successes include the development of liposomal-doxorubicin for cancer treatment. Most assets are early-stage; clinical results depend on individual licensees/spinouts[2][7].

Therapeutic areas: OncologyEndocrinologyRare DiseasesImmunologyHematology
Modalities: AntibodyAAV based gene therapyTCR-T cell therapyRecombinant polypeptideCAR-T cell therapy
Industry: Investors

Partnerships

IBM Alpha Zone/Hadassah AcceleratorHarvard Medical SchoolCanonic/EvogeneIsrael Institute for Biological Research/Tera Novel

Financials

Market cap: $141

Beyond the preview

Go deeper on Hadasit.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hadasit.

Explore the full profile